1887

Abstract

Colistin is a last-resort antibiotic used against carbapenem-resistant (AB); however, colistin resistance has been reported recently. Methylene blue (MB) is used in microbiology for staining, and in medicine as an antidote drug.

We aimed to investigate the antimicrobial effects of MB and eosin methylene blue (EMB) agar against colistin-resistant AB strains.

Firstly, a standard strain and AB clinical isolate were included in the study. After determining MICs, two strains were transformed into colistin-resistant forms, using Li's method. At each step, new MICs were determined and subcultures were inoculated onto EMB and sheep blood agar (SBA). Colistin MICs of the subcultures were also determined using Mueller–Hinton agar (MHA) containing MB. Secondly, colistin-resistant clones from 31 multidrug-resistant AB clinical isolates were screened to investigate their susceptibilities to EMB agar.

In the first round, MICs of both strains had risen to 64 μg ml. Subpopulations with high colistin resistance were inhibited by MB and EMB agar, but could grow well on SBA. In MHA plates containing MB, the MICs decreased to 0.5 μg ml for colistin-susceptible or moderately resistant clones. Additionally, clones with high colistin resistance showed atypical colony morphology on SBA. In the second round, 35 % of the clinical isolates, which had gained resistance to colistin, were inhibited by EMB agar.

MB may have inhibitory effects against colistin-resistant AB. Secondly, using only EMB agar for subculturing may cause missing of colistin-resistant strains.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001078
2019-09-19
2019-10-13
Loading full text...

Full text loading...

References

  1. Murray PR, Rosenthal KS, Pfaller MA. Pseudomonas and related bacteria In Murray PR. ed Medical microbiology, 8th ed. Philadelphia: Elsevier Inc; 2016; pp278–279
    [Google Scholar]
  2. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J et al. Antimicrobial-Resistant pathogens associated with healthcare-associated infections: summary of data reported to the National healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34:1–14 [CrossRef]
    [Google Scholar]
  3. Fritzenwanker M, Imirzalioglu C, Herold S, Wagenlehner FM, Zimmer KP et al. Treatment options for carbapenem- resistant gram-negative infections. Dtsch Arztebl Int 2018;115:345–352 [CrossRef]
    [Google Scholar]
  4. Mendelson M, Brink A, Gouws J, Mbelle N, Naidoo V et al. South African one health stewardship Sub-committee of the Ministerial Advisory Committee on antimicrobial resistance). The one health stewardship of colistin as an antibiotic of last resort for human health in South Africa. Lancet Infect Dis 2018;18:e288–e294
    [Google Scholar]
  5. Arroyo LA, Mateos I, González V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 2009;53:1295–1296 [CrossRef]
    [Google Scholar]
  6. Oikonomou O, Sarrou S, Papagiannitsis CC, Georgiadou S, Mantzarlis K et al. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. BMC Infect Dis 2015;15:559 [CrossRef]
    [Google Scholar]
  7. Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS et al. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis 2012;73:267–270 [CrossRef]
    [Google Scholar]
  8. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012;67:1607–1615 [CrossRef]
    [Google Scholar]
  9. Liu YY, Wang Y, Walsh TR, Yi L-X, Zhang R et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016;16:161–168 [CrossRef]
    [Google Scholar]
  10. Levine M. Differentiation of B. coli and B. aerogens on a simplified Eosin-Methylene blue agar. J Infect Dis. 1918;23:43–47 [CrossRef]
    [Google Scholar]
  11. Wainwright M, Crossley KB. Methylene Blue-a therapeutic dye for all seasons?. J Chemother 2002;14:431–443 [CrossRef]
    [Google Scholar]
  12. Barclay JA, Ziemba SE, Ibrahim RB. Dapsone-induced methemoglobinemia: a primer for clinicians. Ann Pharmacother 2011;45:1103–1115 [CrossRef]
    [Google Scholar]
  13. Mathelin C, Croce S, Brasse D, Gairard B, Gharbi M et al. Methylene blue dye, an accurate dye for sentinel lymph node identification in early breast cancer. Anticancer Res 2009;29:4119–4125
    [Google Scholar]
  14. Pascual A, Henry M, Briolant S, Charras S, Baret E et al. In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs. Antimicrob Agents Chemother 2011;55:2472–2474 [CrossRef]
    [Google Scholar]
  15. Pollack G, Pollack A, Delfiner J, Fernandez J. Parathyroid surgery and methylene blue: a review with guidelines for safe intraoperative use. Laryngoscope 2009;119:1941–1946 [CrossRef]
    [Google Scholar]
  16. CLSI Performance Standards for Antimicrobial Susceptibility Testing CLSI supplement M100, 27th ed. Philadelphia: Clinical and Laboratory Standards Institute; 2017
    [Google Scholar]
  17. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:2946–2950 [CrossRef]
    [Google Scholar]
  18. Oleksiuk LM, Nguyen MH, Press EG, Updike CL, O'Hara JA et al. In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem. Antimicrob Agents Chemother 2014;58:1195–1199 [CrossRef]
    [Google Scholar]
  19. Moffatt JH, Harper M, Adler B, Nation RL, Li J et al. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 2011;55:3022–3024 [CrossRef]
    [Google Scholar]
  20. Soon RL, Nation RL, Cockram S, Moffatt JH, Harper M et al. Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment. J Antimicrob Chemother 2011;66:126–133 [CrossRef]
    [Google Scholar]
  21. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011;55:3370–3379 [CrossRef]
    [Google Scholar]
  22. Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A et al. Colistin-Resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 2015;60:1295–1303 [CrossRef]
    [Google Scholar]
  23. Wand ME, Bock LJ, Bonney LC, Sutton JM. Retention of virulence following adaptation to colistin in Acinetobacter baumannii reflects the mechanism of resistance. J Antimicrob Chemother 2015;70:2209–2216 [CrossRef]
    [Google Scholar]
  24. García-Quintanilla M, Carretero-Ledesma M, Moreno-Martínez P, Martín-Peña R, Pachón J et al. Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii. Int J Antimicrob Agents 2015;46:696–702 [CrossRef]
    [Google Scholar]
  25. Gazel D, Tatman Otkun M, Akçalı A. In-vitro activity of vancomycin against colistin resistant Acinetobacter baumannii strains. Turk Mikrobiyol Cem Derg 2014;44:144–148
    [Google Scholar]
  26. Beceiro A, Moreno A, Fernández N, Vallejo JA, Aranda J et al. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother 2014;58:518–526 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001078
Loading
/content/journal/jmm/10.1099/jmm.0.001078
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error